FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 1, 2013, Pages 19-24

  Moon, Hosik ^a   Chon, Jinyoung ^a   Joo, Jindeok ^b   Kim, Daewoo ^b   In, Janghyeok ^b   Lee, Haejin ^a   Park, Jaesik ^b   Choi, Jinwoo ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

cell mass; FTY720; Sphingosine 1 phosphate

Indexed keywords

FINGOLIMOD; GLUCOSE; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICE; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84872224190     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2341     Document Type: Article

References (32)

1. Ichise M, Harris P. Imaging of β-cell mass and function. J Nucl Med 2010; 51: 1001-1004.
2. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52(1): 102-110.
3. Kan SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46(1): 3-19.
4. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2002; 113(Suppl 6A): 3S-11S.
5. Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88(5): 2300-2308.
6. El-Azab MF, Attia FM, El-Mowafy AM. Novel role of curcumin combined with bone marrow transplantation in reversing experimental diabetes: effects on pancreatic islet regeneration, oxidative stress, and inflammatory cytokines. Eur J Pharmacol 2011; 658(1): 41-48.
7. Lee E, Ryu GR, Ko SH, et al. Antioxidant treatment may protect pancreatic beta cells through the attenuation of islet fibrosis in an animal model of type 2 diabetes. Biochem Biophys Res Commun 2011; 414(2): 397-402.
8. Halban PA, German MS, Kahn SE, Weir GC. Current status of islet cell replacement and regeneration therapy. J Clin Endocrinol Metab 2010; 95(3): 1034-1043.
9. Baumruker T, Billich A, Brinkmann V. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin Investig Drugs 2007; 16(3): 283-289.
10. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277(24): 21453-21457.
11. Verzijl D, Peters SL, Alewijnse AE. Sphingosine-1-phosphate receptors: zooming in on ligand-induced intracellular trafficking and its functional implications. Mol Cells 2010; 29(2): 99-104.
12. Brown BA, Kantesaria PP, McDevitt LM. Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother 2007; 41(10): 1660-1668.
13. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-415.
14. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9(11): 883-897.
15. Maki T, Gottschalk R, Monaco AP. Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantation 2002; 74(12): 1684-1686.
16. Maki T, Gottschalk R, Ogawa N, Monaco AP. Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation 2005; 79(9): 1051-1055.
17. Yang Z, Chen M, Fialkow LB, et al. The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice. Clin Immunol 2003; 107(1): 30-35.
18. Morris MA, McDuffie M, Nadler JL, Ley K. Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells. Autoimmunity 2011; 44(2): 115-128.
19. Alperovich G, Rama I, Lloberas N, et al. New immunosuppressor strategies in the treatment of murine lupus nephritis. Lupus 2007; 16(1): 18-24.
20. Zhao Z, Choi J, Zhao C, Ma ZA. FTY720 normalizes hyperglycemia by stimulating β-cell in-vivo regeneration in db/db mice through the regulation of cyclin D3 and p57KIP2. J Biol Chem 2012; 287(8): 5562-5573.
21. Jung H, Joo J, Jeon Y, et al. Advanced glycation end products downregulate glucokinase in mice. Diabetes Metab Res Rev 2011; 27(6): 557-563.
22. Zhao Z, Zhao C, Zhang XH, et al. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology 2009; 150(6): 2569-2576.
23. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16(1): 35-39.
24. Suzuki S, Li XK, Enosawa S, Shinomiya T. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology 1996; 89(4): 518-523.
25. Matsuda S, Minowa A, Suzuki S, Koyasu S. Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. J Immunol 1999; 162: 3321-3326.
26. Nagahara Y, Ikekita M, Shinomiya T. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol 2000; 165: 3250-3259.
27. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277(24): 21453-21457.
28. Azuma H, Takahara S, Ichimaru N, et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 2002; 62(5): 1410-1419.
29. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14(5): 569-575.
30. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005; 108(3): 308-319.
31. Jörns A, Rath KJ, Terbish T, et al. Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation. Endocrinology 2010; 151(8): 3555-3565.
32. Kendall MR, Hupfeld CJ. FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat diet-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice. Diabetes Obes Metab 2008; 10(9): 802-805.